New drug targets hard-to-treat KRAS mutation in advanced cancers
Disease control
Recruiting now
This early-phase trial tests a new drug called D3S-003 in people with advanced solid tumors that have a specific KRAS p.G12D mutation. The study aims to find a safe dose and check for side effects. About 42 participants whose cancer has worsened after standard treatments will rec…
Phase: PHASE1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated May 01, 2026 15:59 UTC